Etizolam is a thienodiazepine derivative, often researched for its anxiolytic, hypnotic, and anticonvulsant properties. Although it functions similarly to traditional benzodiazepines, its chemical structure includes a thiophene ring in place of a benzene ring, placing it in the thienodiazepine class. It is not approved for medical use in most countries outside of Japan, Italy, and India, and is strictly intended for laboratory research and forensic analysis. Due to its potency and short-acting profile, Etizolam is of particular interest in neuropharmacological studies focused on GABAergic modulation, receptor binding, and acute CNS depression modeling.

• Chemical Classification
  Etizolam is part of the thienodiazepine family, a class of compounds that mimic benzodiazepine activity while structurally differing due to a sulfur atom in the thiophene ring. This gives it a unique pharmacodynamic and metabolic profile.

• Mechanism of Action
  It functions as a positive allosteric modulator at GABA-A receptors, enhancing the effects of GABA and thereby promoting inhibitory neurotransmission in the central nervous system.

• Research Uses
  Etizolam is widely used in scientific research to study anxiety reduction mechanisms, short-acting hypnotics, rapid CNS depression, and benzodiazepine-receptor interaction models.

• Forms Available for Research
  RC Plug supplies Etizolam in powder, pellet, and tablet forms, allowing researchers to choose the most appropriate form for their study design—such as titration, receptor binding assays, or behavioral studies.

• Legal Classification
  It remains a legal gray area in many countries, listed as uncontrolled or unscheduled in some jurisdictions but as a controlled substance in others (e.g., the UK, the US, and Germany).

Etizolam’s pharmacological effects are mediated through modulation of GABA-A receptors, a major class of inhibitory receptors in the brain. By binding to specific benzodiazepine receptor sites, Etizolam enhances the efficacy of GABA (gamma-aminobutyric acid), the brain’s primary inhibitory neurotransmitter, leading to decreased neuronal excitability. This mechanism underpins its anxiolytic, sedative, and muscle-relaxant properties commonly observed in research environments.

• GABAergic Modulation
  Etizolam increases the frequency of chloride ion channel opening at GABA-A receptors, amplifying GABA’s natural calming effect and producing CNS depression.

• Rapid Onset of Action
  In animal and cell-based studies, Etizolam exhibits a quick onset—often within 30 to 60 minutes—making it ideal for short-term, acute research models.

• Shorter Duration Compared to Classical Benzodiazepines
  Etizolam’s half-life (6–8 hours) makes it a preferred compound for researchers studying temporary anxiolytic or hypnotic responses without prolonged downstream effects.

• Selective Receptor Affinity
  Research shows that Etizolam may have a higher selectivity for alpha-2 and alpha-3 subunit-containing GABA-A receptors, which are implicated more strongly in anxiolytic activity than sedative effects.

• Dose-Dependent Effects
  The compound’s CNS effects scale with dosage, ranging from mild anxiolysis at low doses to profound sedation and amnesia at higher levels, allowing researchers to observe varying thresholds of neuroinhibition.

Though both compounds act on GABA-A receptors and exhibit anxiolytic properties, Etizolam and Diazepam differ significantly in their chemical class, duration of action, potency, and therapeutic index. Etizolam is structurally a thienodiazepine, while Diazepam is a classical benzodiazepine. These differences have a measurable impact on receptor binding affinity, onset time, metabolic profile, and practical applications in research.

• Chemical Structure
  Etizolam has a thiophene ring in place of the benzodiazepine benzene ring, giving it distinct metabolic and binding characteristics.

• Potency
  Etizolam is approximately 6–10 times more potent than Diazepam by weight, meaning a 1mg Etizolam dose may yield effects similar to 10mg of Diazepam.

• Half-Life
  Etizolam has a significantly shorter half-life (6–8 hours), making it more suitable for short-acting models. Diazepam has a long half-life (20–100 hours), leading to accumulation and prolonged effects in long-term studies.

• Therapeutic Window
  Etizolam tends to have a narrower therapeutic window, making precise dosing in research essential. Diazepam has a wider margin of safety in pharmacological contexts.

• Use in Research
  Etizolam is frequently used to study rapid-onset anxiolytics, whereas Diazepam is often used for modeling long-term anxiolytic or muscle-relaxant therapies.

The legality of Etizolam varies widely depending on jurisdiction. It is considered a controlled substance in several countries, while in others, it remains unregulated and legal to purchase for research purposes. RC Plug adheres strictly to international shipping protocols and only fulfills orders to countries where Etizolam is not classified as a restricted substance.

• Legal Status by Country
  In the United States and the United Kingdom, Etizolam is classified as a Schedule I/Class C controlled substance respectively. In contrast, it is legal and even prescribed in Japan and India for medical use.

• Research-Only Use
  We provide Etizolam strictly for laboratory, forensic, and analytical research purposes. It is not sold for human consumption or therapeutic use.

• Compliance Responsibility
  Buyers are responsible for understanding their local laws before purchasing. RC Plug does not ship to countries or regions where Etizolam is controlled.

• Stealth Shipping for Non-Controlled Zones
  For permitted destinations, we use discreet packaging and customs-safe shipping techniques to minimize any import issues.

• Refusal of Shipments to Banned Areas
  If Etizolam is prohibited in your region, we will not process the order and may contact you for an alternative solution or refund.

The appropriate research dosage of Etizolam depends on the form (powder, pellet, or tablet), research purpose, test subject, and experimental design. Because of its high potency and narrow margin of error, dosage must be calculated with precision and administered by professionals using calibrated equipment. These guidelines are provided strictly for laboratory use and not for human or animal consumption.

• Common Pellet Doses
  Research pellets typically contain between 0.25mg and 2mg of Etizolam. These fixed doses are used in receptor-binding or behavioral response models.

• Powder Dosing
  For powdered form, microgram-precise scales (0.0001g accuracy) are essential. A typical dose for in vitro experiments may range from 0.1mg to 2mg depending on concentration needs.

• Titration Studies
  Researchers conducting dose-response trials may begin with sub-threshold amounts and increase incrementally to monitor threshold effects, receptor saturation, or behavioral changes.

• Chronic Exposure Models
  For long-term research, dosage is often lower but administered consistently across time intervals to study tolerance, receptor downregulation, or withdrawal phenomena.

• Control and Safety Protocols
  All dosing should be executed with lab safety standards including ventilation, protective wear, and disposal protocols for controlled substances.

Etizolam is a synthetic thienodiazepine with a unique molecular structure that influences its pharmacokinetics and receptor affinity. Its physical form is typically crystalline powder or a compact solid when pressed into tablets or pellets. Due to its high potency and susceptibility to degradation under improper storage conditions, it is critical for researchers to understand its complete chemical and physical profile when designing experiments.

• Molecular Formula and Weight
  Etizolam has a molecular formula of C17H15ClN4S and a molecular weight of 342.85 g/mol, indicating a relatively small and potent compound suitable for microdosing-level research.

• CAS Registry Number
  Its CAS Number is 40054-69-1, providing a unique identifier used for cataloging in chemical registries and referencing in scientific literature.

• Physical Appearance
  Etizolam typically appears as an off-white or pale cream crystalline powder. In tablet or pellet form, it is often white and may vary slightly in hue depending on excipients or binders used.

• Solubility Profile
  It is soluble in ethanol, acetone, and DMSO, but only sparingly soluble in water, making it more suitable for alcohol-based or lipid-based solvent systems in research.

• Melting Point and Stability
  Etizolam has a melting point in the range of 147–150°C, and should be stored in a cool, dark, and dry environment to preserve its integrity over time.

• UV Sensitivity
  Prolonged exposure to light and air may cause degradation, particularly in powdered form. This makes UV-resistant packaging essential for long-term storage.

• pKa Value and LogP
  It has a pKa of approximately 3.5 and a LogP of ~2.1, indicating moderate lipophilicity, which facilitates central nervous system penetration and rapid onset of effects in pharmacological testing.

Etizolam serves as a versatile reference compound in many fields of pharmacological and neuroscientific research. Its fast-acting anxiolytic and hypnotic effects, paired with short elimination half-life, make it ideal for studies that explore acute responses to GABAergic modulation, drug interaction models, and sedative-hypnotic mechanisms.

• Anxiolytic Activity Modeling
  Etizolam is frequently used in rodent or in vitro models to observe anxiety-reduction behaviors and GABAergic receptor dynamics in controlled, short-term studies.

• Sedative-Hypnotic Testing
  Its potent sedative properties enable researchers to explore the induction of sleep, reaction time delays, and motor function suppression.

• Tolerance and Dependence Research
  Due to its structural similarity to benzodiazepines, Etizolam is employed in chronic exposure studies to assess the development of tolerance, cross-tolerance, and receptor downregulation over time.

• Receptor Binding Affinity Studies
  Etizolam is used in radioligand binding assays to quantify binding potential at GABA-A receptor subunits, especially alpha-2 and alpha-3 variants implicated in anxiolytic activity.

• Memory and Amnesia Models
  It is used in experiments involving learning and memory, particularly in evaluating the impact of GABAergic modulation on short-term and long-term memory formation.

• Comparative Benzodiazepine Studies
  Etizolam is often used alongside traditional benzodiazepines like Diazepam or Clonazepam to measure relative potency, efficacy, and duration of action under identical conditions.

At RC Plug, we prioritize purity, precision, and consistency. All of our Etizolam products are subjected to rigorous laboratory testing before shipment to ensure each batch meets the highest research-grade standards. Our reputation in the research community is built on delivering chemical compounds with unmatched purity and verified integrity.

• ≥99% Lab-Tested Purity
  Every batch of Etizolam is tested in ISO-accredited laboratories to ensure that the purity is no less than 99%, suitable for sensitive pharmacological and analytical studies.

• Verified with Certificates of Analysis (COAs)
  Each batch comes with a COA showing test results for identity, purity, and structural consistency. Researchers may request these reports at the time of purchase.

• No Fillers or Contaminants
  Our Etizolam is free of binders, dyes, or adulterants, unless specified in compressed forms (pellets or tablets), where pharmaceutical-grade excipients are used solely for consistency.

• Analytical Methodologies
  Testing includes HPLC, NMR spectroscopy, and mass spectrometry to ensure structural integrity and compound verification.

• Batch Consistency
  Every lot undergoes strict quality control to maintain inter-batch consistency, ensuring reproducibility in research settings.

• Packaging to Preserve Purity
  Products are sealed in UV-blocking, airtight, tamper-evident bags to prevent exposure to air and light, minimizing degradation during storage and transit.

To ensure the chemical stability and integrity of Etizolam for long-term research, it must be stored in a controlled environment. Improper storage can lead to chemical degradation, reduced potency, and compromised data outcomes. RC Plug ships Etizolam in protective packaging designed to prolong shelf life and maintain quality from the moment of dispatch.

• Temperature Requirements
  Etizolam should be stored at a temperature below 25°C (77°F). For long-term preservation, refrigeration between 2–8°C may be used but is not essential.

• Humidity Control
  The compound should be kept in a dry, low-humidity environment to avoid clumping or chemical breakdown, particularly in powdered form.

• Light Protection
  Etizolam is light-sensitive, especially in fine powder form. Always store in UV-resistant, opaque containers or pouches.

• Air Exposure
  Once opened, the compound should be handled quickly and resealed immediately using airtight bags or vials to limit oxidation or moisture intrusion.

• Handling Recommendations
  Researchers should use gloves and antistatic tools when handling Etizolam to prevent contamination, skin contact, or static charge affecting the sample.

• Labeling and Documentation
  Store with proper labeling including batch number, date received, and expiration date to ensure accurate tracking and experimental documentation.

Etizolam is known for its rapid onset and relatively short duration of action, making it a preferred compound for researchers studying fast-acting anxiolytic or sedative agents. Its pharmacokinetic profile supports acute modeling of CNS depression, with effects that do not linger beyond 8 hours, thereby minimizing residual interference with post-experimental recovery or follow-up testing.

• Onset of Action
  In human pharmacokinetic models and rodent studies, Etizolam reaches effective plasma concentrations within 30 to 60 minutes of oral administration.

• Time to Peak Effect
  Peak CNS effects typically occur around 90 minutes post-administration, coinciding with peak plasma levels and maximal GABA receptor modulation.

• Total Duration
  Its effects generally last between 6 and 8 hours, depending on dose, subject metabolism, and administration method.

• Elimination Half-Life
  Etizolam has a half-life of approximately 6.2 hours, which supports its role in short-term pharmacological testing without excessive accumulation.

• Minimal Residual Sedation
  Due to its short half-life and clean metabolism, Etizolam is less likely to cause next-day impairment compared to longer-acting benzodiazepines in research animals or simulations.

• Rebound Effect Monitoring
  Its relatively rapid offset allows researchers to study rebound anxiety or insomnia models, critical for evaluating the dynamics of dependency or withdrawal.

Etizolam is frequently used in sleep-related research due to its potent sedative and hypnotic effects. Its fast onset and short half-life make it ideal for studies focusing on sleep induction, latency periods, and the balance between non-REM and REM sleep cycles. Researchers have utilized Etizolam to evaluate the efficacy of short-acting hypnotics and their role in sleep disorders such as insomnia, particularly in preclinical models.

• Rapid Sleep Induction
  Etizolam significantly reduces sleep latency—the time taken to fall asleep—making it valuable in modeling compounds that facilitate fast sleep onset in insomnia-based trials.

• Short Duration, Minimal Residual Effect
  Its relatively short half-life (~6 hours) allows researchers to observe immediate hypnotic effects without long-lasting sedation, helping evaluate morning alertness in rebound models.

• REM and Non-REM Cycle Interaction
  In animal studies, Etizolam has been shown to reduce REM sleep proportionally more than non-REM, an effect often used to analyze the balance of neurotransmitter systems during sleep.

• Sleep Fragmentation Assessment
  Its influence on night-time awakenings and sleep architecture fragmentation is useful for testing interventions that aim to restore continuous sleep cycles.

• Combination with Melatonin or Nootropics
  Etizolam is occasionally co-administered with melatonin or nootropic compounds to evaluate synergistic or antagonistic effects on the circadian rhythm and memory consolidation during sleep.

Etizolam is available in several forms to meet different research objectives, ranging from dosage precision to administration methods. RC Plug provides Etizolam in powder, pellet, and tablet forms, each tailored to suit various experimental setups, whether for chemical titration, dose-response trials, or behavioral observations.

• Powder
  Supplied as a fine off-white crystalline material, ideal for quantitative titration, solubility analysis, and solution-based dosing. Powder offers full flexibility in custom dosing and formulation studies.

• Pellets
  Standardized doses (e.g., 0.5mg, 1mg, 2mg) compressed into small, dense pellets for fixed-dose behavioral studies and rodent model administration, offering high consistency and ease of handling.

• Tablets
  Formulated for more real-world simulation models, especially in pharmacokinetic and bioavailability testing. These are often preferred when simulating human-style ingestion in non-human studies.

• Customization
  At RC Plug, custom dosage levels or bulk powder packaging can be arranged upon request to meet unique study protocols or large-scale institutional needs.

• Stability and Shelf Life
  All forms are sealed in UV-blocking, vacuum-tight containers to prevent oxidation and maintain potency throughout the product’s two-year shelf life.

Etizolam has been shown to impact memory and cognitive function in a dose-dependent manner, primarily through its interaction with GABA-A receptors. In laboratory settings, it is often studied for its potential to induce anterograde amnesia, affect working memory, and modulate executive function. This makes it a critical compound in neuropsychological and psychopharmacological research.

• Anterograde Amnesia
  Like other benzodiazepine-like compounds, Etizolam can impair the formation of new memories while under its influence. This is used in animal models studying hippocampal suppression and transient memory loss.

• Working Memory Impairment
  At higher doses, Etizolam can reduce attention span and interfere with short-term memory, which is useful in testing the cognitive trade-offs of anxiolytics.

• Reversible Cognitive Suppression
  Studies show that Etizolam-induced memory effects are temporary and fully reversible after clearance of the compound, making it suitable for comparative recovery analysis.

• Dose-Sensitivity in Cognitive Models
  Lower doses may not impact memory noticeably, while higher doses lead to clear inhibitory effects, allowing detailed mapping of GABA modulation thresholds on cognition.

• Co-administration with Nootropics
  It is occasionally combined with memory-enhancing compounds to evaluate potential protective or antagonistic cognitive interactions.

Yes, Etizolam, like many GABA-A receptor agonists, demonstrates a measurable risk of physical and psychological dependence in repeated-dose animal studies. These studies are crucial for understanding receptor desensitization, tolerance buildup, and withdrawal syndromes in a controlled environment.

• Tolerance Development
  Repeated Etizolam exposure results in reduced efficacy over time, with observable declines in anxiolytic or sedative response—commonly studied in rodent chronic-use models.

• Receptor Downregulation
  GABA-A receptors become less responsive with long-term exposure, leading to increased dosing requirements for the same effect—a key marker of pharmacological tolerance.

• Withdrawal Symptoms
  Abrupt cessation in rodent models can induce rebound anxiety, restlessness, or muscle tremors, which mirror withdrawal patterns in classical benzodiazepines.

• Cross-Dependence Studies
  Etizolam is used in cross-tolerance experiments to understand whether dependence overlaps with other benzodiazepines or thienodiazepines.

• Neuroadaptation Models
  Research involving chronic Etizolam exposure contributes to understanding neuroplastic changes and receptor remodeling involved in addiction biology.

Etizolam is widely regarded as a suitable compound for pharmacokinetic (PK) and pharmacodynamic (PD) studies due to its well-characterized absorption, distribution, metabolism, and elimination profile. Its distinct structure offers insight into thienodiazepine metabolism, allowing comparisons with traditional benzodiazepines and other CNS depressants.

• Rapid Absorption
  Etizolam reaches peak plasma concentrations quickly (Tmax ≈ 0.5 to 1.5 hours), allowing researchers to accurately chart initial uptake curves.

• Moderate Half-Life
  With a half-life of 6–8 hours, Etizolam provides a clear elimination window suitable for short-term PK studies and multiple-dose trials.

• First-Pass Metabolism
  In hepatic studies, Etizolam undergoes significant first-pass metabolism involving CYP450 enzymes, producing primary metabolites like α-hydroxyetizolam.

• Elimination Pathway
  It is mainly metabolized in the liver and excreted via urine, making it ideal for urinary metabolite profiling, drug interaction, and enzyme induction research.

• High Bioavailability in Oral Studies
  Oral administration shows strong systemic availability, making it a solid candidate for bioequivalence or dosing form comparison trials.

Etizolam is often studied in combination with other pharmacological agents to evaluate synergistic, antagonistic, or additive effects. These combined models are used to explore interactions at the receptor, metabolic, and behavioral levels. However, combining Etizolam with certain compounds may increase risks, and such studies should be conducted under strict lab safety controls.

• GABAergic Synergy Studies
  Etizolam is commonly paired with other GABA-A modulators like phenibut, diazepam, or zolpidem in research to investigate cumulative effects on CNS depression and receptor desensitization.

• Sedative Interaction Testing
  Combining Etizolam with other sedatives or anesthetics (e.g., barbiturates or alcohol analogs) helps researchers understand the additive risks of respiratory depression and motor impairment.

• Nootropic Counterbalance Models
  In cognitive trials, Etizolam is occasionally co-administered with stimulants or nootropics like modafinil or racetams to evaluate whether memory impairment can be offset.

• Antidepressant Compatibility
  Research involving SSRIs or MAOIs explores potential interaction risks with Etizolam, particularly in serotonin and dopamine-related pathways.

• Toxicology Screening
  Etizolam is used in drug interaction panels to measure hepatic enzyme inhibition or induction when combined with antiepileptics, opioids, or antipsychotics.